During the past decade, Miami Kidney Group conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 1 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Miami Kidney Group" are "Chronic Kidney Disease" (1 trials), "Chronic Kidney Diseases" (1 trials), "Hyperphosphatemia" (1 trials), "Iron Deficiency Anemia" (1 trials) and "Renal Insufficiency, Chronic" (1 trials). Many other conditions were trialed in "Miami Kidney Group" in a lesser frequency.

Most popular intervention types in "Miami Kidney Group" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "Calcium-based phosphate binder" (1 trials), "KRX-0502" (1 trials), "Sevelamer hydrochloride" (1 trials) and "paricalcitol" (1 trials). Other intervention names were less common.

The vast majority of trials in "Miami Kidney Group" are 4 trials for "All" genders.

Currently, there are NaN active trials in "Miami Kidney Group". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Miami Kidney Group, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Miami Kidney Group, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".